The group's principal activity is to develop and commercialize innovative small molecule drugs for improving cancer treatments. Small molecule drugs are non-protein products produced by chemical synthesis. The group's two product candidates that are currently under development: rsr13 (efaproxiral) and pdx (10-propargyl-10-deazaaminopterin). Rsr13 is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. Pdx is an injectable small molecule chemotherapeutic agent that has a superior potency and toxicity profile relative to methotrexate and other related dihydrofolate reductase inhibitors.
